Differentiated thyroid cancer and selenium supplements for protection of salivary glands from 131I treatment

被引：0
|
作者：
Mazokopakis, Elias E. [1 ]
机构：
[1] Naval Hosp Crete, Dept Internal Med, Khania 73200, Crete, Greece
来源：
HELLENIC JOURNAL OF NUCLEAR MEDICINE | 2018年 / 21卷 / 01期
关键词：
HASHIMOTOS-THYROIDITIS; MANAGEMENT;
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：83 / 84
页数：2
相关论文
共 50 条
  • [21] Clinical pathway of metabolic therapy with 131I in differentiated thyroid cancer
    Saiz, I. Blanco
    Apinaniz, E. Anda
    Arribas, J. Pineda
    Moreno, F. Caudepon
    Iglesias, A. Fernandez
    Jimenez, M. Huarte
    Munoz, A. I. de Miguel
    Aristorena, M. I. Irigoyen
    Girones, E. Goni
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (03): : 178 - 187
  • [22] Dosimetric approach to 131I ablation therapy for the differentiated thyroid cancer
    Gortan, Fatma Arzu
    Yuksel, Alptug Ozer
    Gulaldi, Nedim Cuneyt Murat
    Coskun, Nazim
    Akca, Ceren Deniz Kapulu
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2022, 25 (03) : 260 - 268
  • [23] Role of 131I in low-risk differentiated thyroid cancer
    Vallejo, J. A.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (01): : 33 - 37
  • [24] Prognostic value of serial 131I scans in patinets with differentiated thyroid cancer after 131I therapy.
    Lu, HK
    Zhu, RS
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 410P - 410P
  • [25] Incidence of Nonthyroidal Primary Malignancy and the Association with 131I Treatment in Patients with Differentiated Thyroid Cancer
    Hirsch, Dania
    Shohat, Tzippy
    Gorshtein, Alex
    Robenshtok, Eyal
    Shimon, Ilan
    Benbassat, Carlos
    THYROID, 2016, 26 (08) : 1110 - 1116
  • [26] Changes in percentage of lymphocyte subsets after 131I treatment in patients with differentiated thyroid cancer
    LUO Quan-Yong
    NuclearScienceandTechniques, 2005, (04) : 214 - 216
  • [27] Dose reduction of 131i ablative therapy for treatment differentiated thyroid cancer in a hospital setting
    Lima, A.
    Garcia-Burillo, A.
    Soriano, B.
    Quera, M.
    Moga, M.
    Modamio, P.
    Castell, J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 986 - 986
  • [28] Do all patients with differentiated thyroid cancer benefit from 131I therapy.
    McDougall, IR
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 324P - 324P
  • [29] Effect of 131I therapy on pulmonary function from pulmonary metastases with differentiated thyroid cancer
    Chen, Pan
    Wei, Ouyang
    Feng, Huijuan
    Wu, Juqing
    Wang, Jing
    Deng, Yuying
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [30] The utility of "blind" 131I treatments for differentiated thyroid cancer: An educational exhibit
    Elboga, Umut
    Orquiza, Michael
    Celen, Y. Zeki
    Aktolun, Cumali
    Van Nostrand, Douglas
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54
12345